FDA Premarket Safety Plan Is Not Cost-Effective Rx Development – PhRMA

Safety requirements outlined in FDA's "Premarketing Risk Assessment" concept paper seem to run counter to Commissioner McClellan's emphasis on cost-effective drug development, the Pharmaceutical Research & Manufacturers of America said during a public workshop on risk management April 9